Skip to main content
Jenkem Technology Co., Ltd. logo

Jenkem Technology Co., Ltd. — Investor Relations & Filings

Ticker · 688356 ISIN · CNE1000043K9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-10-08 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688356

About Jenkem Technology Co., Ltd.

https://www.jenkem.com/

Jenkem Technology Co., Ltd. specializes in the research, development, and large-scale manufacturing of high-purity polyethylene glycol (PEG) derivatives and related polymers. The company provides a comprehensive portfolio of PEG products, including monodisperse and polydisperse PEG linkers, multi-arm PEGs, and functionalized derivatives such as NHS esters, maleimides, and amines. These materials are primarily utilized in advanced drug delivery systems, PEGylation of proteins and peptides, and the development of medical devices and hydrogels. In addition to its core PEG offerings, the company produces biodegradable polymers, including PLA, PLGA, and PCL. Jenkem Technology supports the global biotechnology and pharmaceutical sectors through custom synthesis and high-quality manufacturing processes designed to meet rigorous technical specifications for therapeutic and diagnostic applications.

Recent filings

Filing Released Lang Actions
关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It does not contain financial statements or earnings data, nor is it an annual or interim report. The document is specifically about the company's buyback of its own shares, which fits the definition of a Transaction in Own Shares (POS) filing.
2024-10-08 Chinese
关于自愿披露聚乙二醇伊立替康用于治疗小细胞肺癌III期临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of the first patient enrollment in a Phase III clinical trial for a drug developed by the company. It includes details about the drug, clinical trial progress, and risk warnings. The document is relatively short (1118 characters) and does not contain financial data, earnings, or detailed management discussion. It is an update on a clinical trial progress, which is a regulatory announcement about ongoing R&D activities rather than a financial report or management report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and risk disclosure, which does not fit other specific categories.
2024-09-29 Chinese
关于参加2024年半年度科创板制药及生物制品专场集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in a 2024 semi-annual performance explanation meeting organized by the Shanghai Stock Exchange. It references the company's 2024 semi-annual report already published on August 30, 2024, but the document itself is not the report. It details the meeting time, location, participants, and how investors can join the interactive session. The document is short (1147 characters) and serves as a notice for an investor presentation event rather than containing financial data or the report itself. Therefore, it fits best as an Investor Presentation (IP) announcement rather than the actual report or a report publication announcement (RPA).
2024-09-04 Chinese
关于自愿披露聚乙二醇伊立替康二线单药治疗小细胞肺癌的安全性、耐受性和初步疗效的II期研究在期刊发表的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of clinical trial results for a pharmaceutical product. It details the safety, tolerability, and preliminary efficacy of a phase II study published in an academic journal. The text includes information about the drug development progress, clinical trial phases, and risk warnings. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is an announcement of research results and clinical progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specific announcement about clinical research progress and publication, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2024-09-04 Chinese
关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Beijing Jiankai Technology Co., Ltd. regarding the progress of its share repurchase program conducted via centralized bidding transactions. It details the repurchase plan, including dates, amounts, prices, and cumulative shares repurchased. The document is relatively short (1345 characters) and focuses on the update of the share buyback activity, not a full financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-09-02 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, and other key financial metrics. It also includes shareholder information and company basic information. The document explicitly states it is a half-year report summary and references the full half-year report for detailed information. The length is under 5,000 characters but it contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it is a comprehensive interim/quarterly report for a period shorter than a full fiscal year. Hence, the correct classification is Interim / Quarterly Report (IR). H1 2024
2024-08-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.